However, while treatment with the CCL2 inhibitor mNOX-E36 resulted in a decrease of monocyte/macrophage infiltration and hepatic steatosis in the murine models of carbon tetrachloride- and MCD diet-induced hepatic injury, mNOX-E36 application was not able to alter fibrosis progression [186]. The gene discussed is CCL2; the disease is Hepatic steatosis.